Tumor necrosis factor receptor-associated periodic syndrome managed with the couple alendronate-canakinumab

Donato Rigante, Giuseppe Lopalco, Antonio Vitale, Bruno Frediani, Florenzo Iannone, Luca Cantarini

Research output: Contribution to journalArticle

13 Citations (Scopus)


Management of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is puzzling, and therapeutic choices can be complicated, due to both wide genetic heterogeneity and protean clinical phenotype. We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis. Alendronate combined with canakinumab led to the optimal clinical control of all TRAPS manifestations and normalization of inflammatory markers. Further studies should be performed to clarify bisphosphonates' role in the scenery of autoinflammatory disorders.
Original languageEnglish
Pages (from-to)807-809
Number of pages3
Publication statusPublished - 2015


  • Alendronate

Fingerprint Dive into the research topics of 'Tumor necrosis factor receptor-associated periodic syndrome managed with the couple alendronate-canakinumab'. Together they form a unique fingerprint.

Cite this